source
- FDA proposes removing obesity and diabetes drug ingredients from compounding substances listThe U.S. Food and Drug Administration has issued a proposal to remove the active ingredients of widely used obesity and diabetes medicines from the list of substances that can be compounded. The ch…
- Seaport and Hemab price IPOs as Avalyn soars on Nasdaq debutThree biotechnology companies announced the pricing of their initial public offerings between Thursday and Friday, collectively targeting more than $850 million in proceeds. Seaport Therapeutics a…